ATARA BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.69 USD | -1.40% |
|
+4.39% | +34.56% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 891.9 | 1,626 | 1,393 | 311.2 | 52.27 | 83.09 | - | - |
| Enterprise Value (EV) 1 | 632.8 | 1,125 | 1,022 | 68.24 | 0.3947 | 35.58 | 25.72 | -58.06 |
| P/E ratio | -2.9 x | -4.73 x | -4.34 x | -1.46 x | -0.2 x | -0.87 x | -1.99 x | -1.15 x |
| Yield | - | - | - | - | - | 290% | 290% | 290% |
| Capitalization / Revenue | - | - | 68.5 x | 4.9 x | 6.1 x | 0.85 x | 1 x | 0.98 x |
| EV / Revenue | - | - | 50.3 x | 1.07 x | 0.05 x | 0.36 x | 0.31 x | -0.69 x |
| EV / EBITDA | -2.19 x | -3.74 x | -3.09 x | -0.25 x | -0 x | -0.69 x | -0.23 x | 0.54 x |
| EV / FCF | -2.62 x | -6.07 x | -4.42 x | -0.25 x | -0 x | -1.32 x | -0.34 x | 1.45 x |
| FCF Yield | -38.1% | -16.5% | -22.6% | -402% | -49,198% | -75.9% | -295% | 68.9% |
| Price to Book | 3.22 x | 3.14 x | 5.28 x | 2.64 x | - | - | - | - |
| Nbr of stocks (in thousands) | 54,151 | 82,816 | 88,417 | 94,879 | 101,922 | 120,416 | - | - |
| Reference price 2 | 16.47 | 19.63 | 15.76 | 3.280 | 0.5128 | 0.6900 | 0.6900 | 0.6900 |
| Announcement Date | 2/27/20 | 3/1/21 | 2/28/22 | 2/8/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 20.34 | 63.57 | 8.573 | 98.05 | 83.06 | 84.61 |
| EBITDA 1 | -288.6 | -300.7 | -331.1 | -274.9 | -271.2 | -51.62 | -111.8 | -107.7 |
| EBIT 1 | -295.7 | -309.1 | -340.5 | -280.5 | -276 | -85.09 | -64.44 | -94.76 |
| Operating Margin | - | - | -1,673.85% | -441.25% | -3,219.48% | -86.79% | -77.59% | -111.99% |
| Earnings before Tax (EBT) 1 | -291 | -306.6 | -340.1 | -228.3 | -276.1 | -89 | -50.25 | -80.5 |
| Net income 1 | -291 | -306.6 | -340.1 | -228.3 | -276.1 | -94.59 | -48.22 | -80.5 |
| Net margin | - | - | -1,672.28% | -359.12% | -3,220.88% | -96.48% | -58.05% | -95.14% |
| EPS 2 | -5.670 | -4.150 | -3.630 | -2.240 | -2.610 | -0.7933 | -0.3467 | -0.6000 |
| Free Cash Flow 1 | -241.4 | -185.3 | -231.1 | -274.6 | -194.2 | -27 | -76 | -40 |
| FCF margin | - | - | -1,136.19% | -431.98% | -2,265.25% | -27.54% | -91.5% | -47.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | 2.000 | 2.000 | 2.000 |
| Announcement Date | 2/27/20 | 3/1/21 | 2/28/22 | 2/8/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.37 | 7.548 | 7.314 | 51.58 | 4.459 | 0.221 | 1.226 | 0.957 | 2.138 | 4.252 | 24.69 | 31.3 | 11.17 | 49.9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -84.81 | -93.4 | -88.22 | -32.13 | -84.62 | -75.54 | -75.02 | -71.41 | -69.61 | -59.96 | -31.35 | -16.41 | -35.17 | 5.156 |
| Operating Margin | -1,579.37% | -1,237.45% | -1,206.18% | -62.3% | -1,897.78% | -34,180.54% | -6,118.92% | -7,462.28% | -3,255.94% | -1,410.21% | -126.96% | -52.41% | -314.8% | 10.33% |
| Earnings before Tax (EBT) 1 | -84.66 | -93.32 | -88.1 | 18.47 | -84.08 | -74.57 | -74.75 | -71.11 | -69.82 | -60.44 | -32.2 | -15.5 | -33.3 | -8.05 |
| Net income 1 | -84.66 | -93.35 | -88.1 | 18.47 | -84.09 | -74.57 | -74.77 | -71.11 | -69.8 | -60.45 | -32.2 | -15.5 | -33.3 | -8.05 |
| Net margin | -1,576.61% | -1,236.74% | -1,204.61% | 35.8% | -1,885.87% | -33,742.99% | -6,098.78% | -7,430.3% | -3,264.59% | -1,421.68% | -130.42% | -49.52% | -298.08% | -16.13% |
| EPS 2 | -0.9000 | -0.9600 | -0.8700 | 0.1800 | -0.8200 | -0.7200 | -0.7200 | -0.6800 | -0.6600 | -0.5600 | -0.2500 | -0.1300 | -0.2450 | -0.0750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/28/22 | 5/5/22 | 8/8/22 | 11/8/22 | 2/8/23 | 5/8/23 | 8/8/23 | 11/1/23 | 3/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 259 | 501 | 371 | 243 | 51.9 | 47.5 | 57.4 | 141 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -241 | -185 | -231 | -275 | -194 | -27 | -76 | -40 |
| ROE (net income / shareholders' equity) | -92.4% | -81.4% | -91.7% | -54.1% | - | - | - | - |
| ROA (Net income/ Total Assets) | -79.2% | -65.9% | -64.4% | -112% | - | - | - | - |
| Assets 1 | 367.4 | 465.6 | 528.1 | 203.1 | - | - | - | - |
| Book Value Per Share | 5.120 | 6.250 | 2.990 | 1.240 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 5.73 | 4.51 | 10.6 | 4.19 | 1.22 | 0.4 | 8 | 10 |
| Capex / Sales | - | - | 52.02% | 6.6% | 14.27% | 0.41% | 9.63% | 11.82% |
| Announcement Date | 2/27/20 | 3/1/21 | 2/28/22 | 2/8/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.69
USD
Average target price
4.2
USD
Spread / Average Target
+508.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.56% | 82.36M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ATRA Stock
- Financials Atara Biotherapeutics, Inc.
